FY2028 Earnings Estimate for DVAX Issued By William Blair

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Analysts at William Blair issued their FY2028 earnings per share estimates for Dynavax Technologies in a research report issued to clients and investors on Wednesday, June 4th. William Blair analyst M. Phipps expects that the biopharmaceutical company will post earnings per share of $1.18 for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. The Goldman Sachs Group reduced their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. JMP Securities reduced their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $24.00.

Dynavax Technologies Stock Performance

Shares of DVAX traded up $0.29 during mid-day trading on Thursday, hitting $10.24. 1,408,713 shares of the company's stock were exchanged, compared to its average volume of 2,204,428. Dynavax Technologies has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The firm has a market capitalization of $1.23 billion, a P/E ratio of 56.89 and a beta of 1.06. The business's 50 day moving average is $10.66 and its two-hundred day moving average is $12.24. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Institutional Investors Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Deep Track Capital LP lifted its position in shares of Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after acquiring an additional 5,265,000 shares during the period. Deerfield Management Company L.P. Series C lifted its position in shares of Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock valued at $66,325,000 after acquiring an additional 5,172,263 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Dynavax Technologies by 4.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock valued at $51,948,000 after acquiring an additional 171,933 shares during the period. Renaissance Technologies LLC increased its stake in shares of Dynavax Technologies by 1.8% during the 4th quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company's stock worth $30,077,000 after purchasing an additional 41,000 shares in the last quarter. Finally, Blair William & Co. IL raised its position in shares of Dynavax Technologies by 0.5% during the 1st quarter. Blair William & Co. IL now owns 2,272,707 shares of the biopharmaceutical company's stock worth $29,477,000 after purchasing an additional 11,030 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.